All articles by William Newton

William Newton is a Senior Reporter for Clinical Trials Arena and Pharmaceutical Technology, focusing on clinical trial design, healthcare business and regulation, and new technologies. Now based in New York City, he previously covered diabetes drug development at Close Concerns’ industry-facing publication in San Francisco. William holds a BA in Economics from Williams College.

William Newton


Intra-Cellular reports positive Phase III trial of Caplyta in MDD and bipolar depression

Intra-Cellular’s Caplyta met the primary and key secondary endpoints of a Phase III trial for mixed features of major depressive disorder and bipolar depression.

FDA to hold Advisory Committee meeting for BrainStorm’s NurOwn in ALS

In a surprising about-face, the FDA will convene an Advisory Committee to review BrainStorm Cell Therapeutics’s stem cell therapy NurOwn for ALS.

FDA AdCom overwhelmingly supports accelerated approval for Biogen’s tofersen in ALS

AdCom panelists backed an accelerated approval for Biogen’s tofersen in a rare form of ALS based on a new surrogate biomarker.

Rett syndrome: How does Acadia’s trofinetide compare to ANAVEX2-73?

Now that Acadia’s trofinetide nabbed the first FDA approval for Rett syndrome, here’s a look at how Anavex’s Phase III candidate stacks up.

Duchenne muscular dystrophy: major trials and events to watch in 2023

A possible gene therapy approval and a series of major trials readouts set the stage for a busy year of drug development in Duchenne muscular dystrophy.

FDA meeting highlights patient recruitment challenges on Rare Disease Day

For Rare Disease Day, FDA speakers and patient advocates discuss strategies for recruiting diverse patients and paediatric populations for rare disease clinical trials.

Q&A: Ethics of ultra-rare disease drug development and expanded access

Bioethicist Alison Bateman-House, PhD, discusses the ethics of developing rare disease treatments with equity and access in mind.

Quantum medicine: how quantum computers could change drug development

Advances in quantum computing could unlock drug development problems that are too complex for classical computers, but the emerging technology still faces key hurdles.

Delaying type 1 diabetes progression: major trial readouts to watch in 2023

Four clinical trials aim to slow or delay type 1 diabetes progression, but each targets different patients and assesses different endpoints.